Last updated on June 2019

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive HIV-1 and Hepatitis B Co-Infected Adults


Brief description of study

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.

Clinical Study Identifier: NCT03547908

Find a site near you

Start Over

Spectrum Medical Group

Phoenix, AZ United States
  Connect »

Be Well Medical Center

Berkeley, CA United States
  Connect »

Whitman-Walker Health

Washington, WA United States
  Connect »

Midway Immunology & Research

Fort Pierce, FL United States
  Connect »

AIDS Healthcare Foundation (AHF)

Miami Beach, FL United States
  Connect »

Orlando Immunology Center

Orlando, FL United States
  Connect »

University of Florida

Tampa, FL United States
  Connect »

Triple O Research Institute, P.A.

West Palm Beach, FL United States
  Connect »

Howard Brown Health Center

Chicago, IL United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

Southampton Healthcare, Inc.

Saint Louis, MO United States
  Connect »

Rosedale Infectious Diseases

Huntersville, NC United States
  Connect »

Queen Elizabeth Hospital

Kota Kinabalu, Malaysia
  Connect »

Hospital Kuala Lumpur

Kuala Lumpur, Malaysia
  Connect »

Hospital Pulau Pinang

Pulau Pinang, Malaysia
  Connect »

Sungai Buloh Hospital

Sungai Buloh, Malaysia
  Connect »

Seoul Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.